GlassScriptPhysician profile
William E Steffes
NPI 1578855300
$29,824.62
in general payments reported to CMS, 2019-2025
35 companies · $17K in 2025
The $17K reported for 2025 was more than what 93% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,869 · 2020: $897 · 2021: $1,786 · 2022: $2,264 · 2023: $3,393 · 2024: $3,058 · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $13K · Food and Beverage: $9,153 · Education: $523 · Travel and Lodging: $133.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,200.00 |
| Food and Beverage | $9,153.49 |
| Education | $522.97 |
| Travel and Lodging | $133.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $13,825.61 | 2021-2025 | Nemluvio |
| Abbvie INC. | $3,092.77 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $1,293.57 | 2019-2025 | Dupixent, Libtayo |
| Novartis Pharmaceuticals Corporation | $1,271.14 | 2019-2025 | |
| Lilly USA, LLC | $1,194.50 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| E.R. Squibb & Sons, L.L.C. | $1,146.32 | 2022-2025 | Sotyktu |
| Genzyme Corporation | $1,041.85 | 2021-2025 | |
| Janssen Biotech, INC. | $1,032.54 | 2019-2025 | Tremfya |
| Ucb, INC. | $1,025.94 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $936.21 | 2019-2025 | |
| Leo Pharma INC. | $904.37 | 2021-2025 | Adbry, Spevigo, Anzupgo |
| Sun Pharmaceutical Industries INC. | $679.86 | 2019-2025 | Ilumya, Odomzo, Blu-U |
| Amgen INC. | $443.92 | 2020-2025 | Otezla, Otezla |
| Mayne Pharma Commercial LLC | $399.31 | 2019-2025 | |
| Genentech USA, INC. | $278.22 | 2019-2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $225.68 | 2019-2021 | |
| Janssen Scientific Affairs, LLC | $143.11 | 2019-2023 | Tremfya |
| Almirall LLC | $105.52 | 2021-2025 | Klisyri, Seysara |
| Dermavant Sciences, INC. | $100.83 | 2022-2024 | Vtama |
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.15 | 2023-2025 | Spevigo |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $78.59 | 2019-2021 | |
| Dermira, INC. | $68.85 | 2019-2021 | |
| Strata Skin Sciences, INC. | $67.11 | 2020-2022 | |
| Biofrontera INC. | $64.35 | 2023 | Xepi, Bf-Rhodoled, Ameluz |
| Botanix Sb INC | $59.83 | 2025 | Sofdra |
| Arcutis Biotherapeutics, INC. | $43.27 | 2023-2025 | Zoryve |
| Blueprint Medicines Corporation | $41.52 | 2022-2024 | Ayvakit |
| Kerecis Limited | $30.75 | 2022-2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Celgene Corporation | $24.19 | 2019 | |
| Lnhc, INC | $21.97 | 2025 | Zelsuvmi |
| Dusa Pharmaceuticals, INC. | $21.88 | 2019 | |
| Vyne Pharmaceuticals INC. | $19.18 | 2020 | |
| Organogenesis INC. | $19.17 | 2024 | |
| Incyte Corporation | $15.27 | 2022 | |
| Organon LLC | $13.27 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Steffes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.